Nasdaq gnlx.

Genelux | 726 followers on LinkedIn. Genelux Corporation (NASDAQ: GNLX) is a late clinical-stage biotechnology company focused on improving the lives of patients affected by difficult-to-treat solid tumors. Our ChoiceTM Discovery Platform is the foundation of our oncolytic immunotherapy development, having produced over 500 different versions of …GNLX) stock’s latest price update. Genelux Corp (NASDAQ: GNLX)’s stock price has gone rise by 8.96 in comparison to its previous close of 14.51, however, the company has experienced a -15.41% decrease in its stock price over the last five trading days.Genelux Corporation (NASDAQ:GNLX) fell 8.7% to $10.83. Chegg, Inc. (NYSE:CHGG) shares declined 8.2% to $9.60. Morgan Stanley downgraded Chegg from Equal-Weight to Underweight and lowered the price ...WESTLAKE VILLAGE, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Lourie S. Zak will join the ...Web

0. Barclays PLC, a global financial services firm, recently acquired a new stake in Genelux Co. (NASDAQ:GNLX) during the first quarter of this year. According to its latest filing with the Securities and Exchange Commission (SEC), Barclays purchased 33,178 shares of Genelux’s stock, valued at approximately $920,000.In connection with the offering, the Company’s shares are expected to begin trading on the Nasdaq Capital Market under the ticker symbol “GNLX” on January 26, 2023 subject to final approval ...

On September 12, 2023, 10% owner Aladar Szalay sold 52,616 shares of Genelux Corp (NASDAQ:GNLX). Sep 14, 2023. finance.yahoo.com . Genelux General Counsel Awarded $830K Worth of Stock Options - Benzinga. Sep 13, 2023. www.benzinga.com . Read more news. Frequently Asked Questions regarding Genelux.As of this writing, Genelux Corp (NASDAQ:GNLX) shares are trading at above $22.30 with a 52-week range of $5.35 to $39.27, giving the company a market capitalization of more than $527 million. 2 ...

WESTLAKE VILLAGE, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced a private placement of 1,665,247 ...Web29. 3. 2023 ... is redefining immuno-oncology. $GNLX is a late clinical-stage biotechnology company focused on improving the lives of patients affected by ...WESTLAKE VILLAGE, Calif., June 22, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that it will be added to the broad ...HC Wainwright began coverage on shares of Genelux (NASDAQ:GNLX Free Report) in a research report sent to investors on Monday, MarketBeat reports. The brokerage ...

GNLX | Complete Genelux Corp. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.Web

GNLX GNLX Genelux Corp NASDAQ 20.01 -0.03 -0.15% After Hours: 20.01 0 0.00% 16:01 10/19 EDT OPEN 20.00 PREV CLOSE 20.04 HIGH 20.40 LOW 20.00 VOLUME 101.28K …

Genelux Corporation (NASDAQ:GNLX) is a California based biotechnology firm that develops treatments for pancreatic, ovarian, and lung cancer. Its shares are rated Buy on average and analysts have ...WebThe latest price target for . Dyne Therapeutics (NASDAQ: DYN) was reported by JP Morgan on Wednesday, August 9, 2023.The analyst firm set a price target for 22.00 expecting DYN to rise to within ...WESTLAKE VILLAGE, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Lourie S. Zak will join the ...Nasdaq provides visual representation of analyst expected earnings growth. Read our earnings report guide before you consider the forecast information when making investment decisions. Visit the ...WebGenelux Corporation (GNLX) NasdaqCM - NasdaqCM Real Time Price. Currency in USD. Follow. 2W 10W 9M. 11.70 +1.24 (+11.85%) At close: 04:00PM EST. 11.76 +0.06 …

Genelux IPO prices at bottom of range. Genelux Corp. priced its initial public offering at $6 a share, the low end of its $6 to $7 a share range, for its stock market debut Thursday on the Nasdaq under the symbol GNLX. With 2.5 million sha... 11 months ago - Market Watch.Genelux Stock Price, News & Analysis (NASDAQ:GNLX) $11.90 +0.20 (+1.71%) (As of 11/30/2023 ET) Compare Today's Range $11.46 $12.00 50-Day Range …WESTLAKE VILLAGE, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO ...Jun 29, 2023 · WESTLAKE VILLAGE, Calif., June 29, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX) and TVAX Biomedical, Inc. today announced that the United States Patent and Trademark Office granted ... WESTLAKE VILLAGE, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX) (“Genelux” or “the Company”), a late clinical-stage biopharmaceutical company focused on ...On September 12, 2023, 10% owner Aladar Szalay sold 52,616 shares of Genelux Corp (NASDAQ:GNLX). Sep 14, 2023. finance.yahoo.com . Genelux General Counsel Awarded $830K Worth of Stock Options - Benzinga. Sep 13, 2023. www.benzinga.com . Read more news. Frequently Asked Questions regarding Genelux.Genelux Corporation (NASDAQ:GNLX) is a California based biotechnology firm that develops treatments for pancreatic, ovarian, and lung cancer. Its shares are rated Buy on average and analysts have ...

Feb 1, 2023 · Nasdaq Insider Activity page provides trading information of corporate insiders (officers, directors and any beneficial owners of more than 10% of a class of the company’s equity securities). An ... WESTLAKE VILLAGE, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second ...

Nov 24, 2023 · Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian ... Genelux (Nasdaq:GNLX) - Stock Price, News & Analysis - Simply Wall St Stocks / United States / Pharmaceuticals & Biotech GNLX Genelux NasdaqCM:GNLX …GNLX - Genelux Corp - Stock screener for investors and traders, financial ... Genelux Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).WESTLAKE VILLAGE, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the third ...WESTLAKE VILLAGE, Calif., June 12, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced a private placement for 900,000 shares of the Company's common stock at a purchase price of $20.00 per share, for gross proceeds of approximately $18 million, …Webull offers Genelux Corp stock information, including NASDAQ: GNLX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GNLX stock news, and many more online research tools to help you make informed decisions.Genelux Corporation's (NASDAQ:GNLX) value has fallen 16% in the last week, but insiders who sold US$11m worth of stock over the last year have had less success. Insiders might have been better off holding onto their shares, given that the average selling price of US$23.49 is still below the current share price.NASDAQ:GNLX. Exchange/Ticker 2: N/A. Latest Market Cap: $311,897,408. BioCentury | Aug 28, 2023. Management Tracks. Kurt Graves takes top spot at i2o. Plus ...

Nasdaq Insider Activity page provides trading information of corporate insiders (officers, directors and any beneficial owners of more than 10% of a class of the company’s equity securities). An ...

Genelux (NASDAQ:GNLX) said it has received fast-track status from the FDA for its Olvi-Vec program for the treatment of platinum resistant/refractory ovarian cancer. The company is currently ...

29. 3. 2023 ... is redefining immuno-oncology. $GNLX is a late clinical-stage biotechnology company focused on improving the lives of patients affected by ...Jun 29, 2023 · WESTLAKE VILLAGE, Calif., June 29, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX) and TVAX Biomedical, Inc. today announced that the United States Patent and Trademark Office granted ... Jul 6, 2023 · The average one-year price target for Genelux (NASDAQ:GNLX) has been revised to 32.13 / share. This is an increase of 80.00% from the prior estimate of 17.85 dated June 1, 2023. Nov 14, 2023 · WESTLAKE VILLAGE, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the third ... Top 25 Mutual Funds Where Should I Retire? Top 25 ETFs MarketWatch Picks Close Search Overlay $749.20K Ex-Dividend Date % of Float Shorted Oct. 27, 2023 at 1:30 …Find the latest historical data for Genelux Corporation Common Stock (GNLX) at Nasdaq.com.May 15, 2023 · Follow. WESTLAKE VILLAGE, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced a private placement of ... WESTLAKE VILLAGE, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that on September 11, 2023, the ...On June 16, 2023, the NASDAQ:GNLX stock opened at $34.06, representing a significant increase from its one-year low of $5.35 and a modest uptick from its impressive one-year high of $39.27. The stock’s 50-day simple moving average is currently resting at $26.83, indicating a positive trend that is grabbing the attention of expert market analysts.Genelux press release (NASDAQ:GNLX): Q2 GAAP EPS of -$0.23.; At June 30, 2023, the company had cash on hand in the amount of $27.1 million. Net loss was $5.8 million for the second quarter of 2023 ...Genelux ( NASDAQ: GNLX) said it has received fast-track status from the FDA for its Olvi-Vec program for the treatment of platinum resistant/refractory ovarian cancer. The company is currently ...

Genelux Corporation (NASDAQ:GNLX) fell 8.1% to $5.65. Genelux announced pricing of $15 million initial public offering of 2.5 million shares of common stock at a price of $6 per share.Price Target. $25.00. Profile Analyst Ratings Chart Competitors Earnings Financials Insider Trades Institutional Ownership Headlines SEC Filings Short Interest Social Media. Current. Insider Ownership. Percentage. 11.70%. Number Of.GNLX - Genelux Corp - Stock screener for investors and traders, financial ... Genelux Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).Instagram:https://instagram. activision stockshow to see if gold is realbenzinga pro couponhoka stock $173.22 +6.56 3.94%Genelux Corporation Common Stock (GNLX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. sofi optionsbest utility etf According to the issued ratings of 3 analysts in the last year, the consensus rating for Genelux stock is Buy based on the current 3 buy ratings for GNLX. The average twelve-month price prediction for Genelux is $25.00 with a high price target of $40.00 and a low price target of $10.00. Learn more on GNLX's analyst rating history. cheap option trading See the latest Genelux Corp stock price (GNLX:XNAS), related news, valuation, dividends and more to help you make your investing decisions.Genelux Corporation (NASDAQ: GNLX) is a late clinical-stage biotechnology company focused on improving the lives of patients affected by difficult-to-treat solid tumors. Our ChoiceTM Discovery ...WESTLAKE VILLAGE, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second ...